The Synergy Between a Silver‐Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage
Molecular Microbiology · 2026
DOI: 10.1111/mmi.70094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Microbiology, 2026. Verfasst von Emmanuel P Oladokun und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Illinois State University, Normal, Illinois, USA. Hauptthemen laut MEDLINE: Silver, Aminoglycosides, Anti-Bacterial Agents, Ruthenium. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The rise of multidrug‐resistant (MDR) bacterial pathogens, including uropathogenic Escherichia coli (UPEC), highlights the urgent need for alternative treatment strategies to restore antibiotic efficacy. The silver‐ruthenium antimicrobial AGXX exerts potent bactericidal effects through the production of reactive oxygen species (ROS); however, its potential synergy with antibiotics has not been thoroughly investigated. Here, we show that sublethal concentrations of AGXX strongly enhance aminoglycoside‐mediated killing across a diverse panel of Gram‐negative and Gram‐positive MDR clinical isolates, including highly aminoglycoside‐resistant strains. Combinational treatments significantly reduced the effective concentrations of gentamicin, tobramycin, kanamycin, and amikacin required to kill bacteria. Mechanistic analyses revealed that AGXX/aminoglycoside co‐treatments induce pronounced intracellular ROS accumulation, resulting in an imbalanced proteostasis due to extensive protein aggregation and DNA damage. Scavenging ROS abolished synergistic killing, establishing oxidative imbalance as the primary driver of the synergy between both antimicrobials. We further identified polyphosphate as a key bacterial defense mechanism that mitigates ROS accumulation, proteotoxicity, and genotoxic stress during combinational treatment. Moreover, AGXX–aminoglycoside synergy was preserved in an artificial urine medium and across clinical UPEC isolates, underscoring its relevance to urinary tract infections. Together, these findings position AGXX as a potent aminoglycoside adjuvant that restores antibiotic efficacy through ROS‐driven macromolecular damage, supporting its development for combination therapies against MDR bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, Illinois State University, Normal, Illinois, USA.
ORCID-Profile: Jan-Ulrik Dahl
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Oladokun, E. P., Donkor, G. Y., Narh, J. K., Jacobson, G. D., Ward, C., Tawiah, P. O., Polzer, L. K., Edwards, K. A., Floyd, K. A., & Dahl, J. U. (2026). The Synergy Between a Silver‐Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage. Molecular Microbiology. https://doi.org/10.1111/mmi.70094
Vancouver
Oladokun EP, Donkor GY, Narh JK, Jacobson GD, Ward C, Tawiah PO, et al. The Synergy Between a Silver‐Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage. Molecular Microbiology. 2026. doi:10.1111/mmi.70094
BibTeX
@article{Oladokun2026,
author = {Oladokun, Emmanuel P and Donkor, Gracious Y and Narh, Julius K and Jacobson, Grady D and Ward, Cade and Tawiah, Patrick O and Polzer, Lisa K and Edwards, Kevin A and Floyd, Kyle A and Dahl, Jan-Ulrik},
title = {The Synergy Between a Silver‐Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage},
journal = {Molecular Microbiology},
year = {2026},
doi = {10.1111/mmi.70094}
}
EUVIMED